BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Average Rating of “Moderate Buy” from Brokerages

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $42.60.

Several equities research analysts have recently issued reports on BTAI shares. Canaccord Genuity Group reduced their target price on BioXcel Therapeutics from $112.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a research note on Wednesday. They set a “buy” rating and a $65.00 price target for the company. RODMAN&RENSHAW raised shares of BioXcel Therapeutics to a “strong-buy” rating in a research report on Wednesday. Bank of America restated an “underperform” rating and set a $4.00 target price (down previously from $112.00) on shares of BioXcel Therapeutics in a research report on Tuesday, January 7th. Finally, HC Wainwright reduced their price target on BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, January 30th.

BioXcel Therapeutics Trading Down 0.4 %

Shares of BTAI opened at $2.36 on Friday. The business’s 50 day moving average is $3.61 and its 200 day moving average is $6.77. BioXcel Therapeutics has a 12-month low of $1.72 and a 12-month high of $49.58. The company has a market capitalization of $7.57 million, a PE ratio of -0.07 and a beta of 0.89.

Institutional Trading of BioXcel Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of BTAI. Geode Capital Management LLC increased its holdings in BioXcel Therapeutics by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock worth $117,000 after purchasing an additional 13,922 shares during the period. Wells Fargo & Company MN grew its position in shares of BioXcel Therapeutics by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after buying an additional 13,952 shares in the last quarter. Northern Trust Corp increased its stake in shares of BioXcel Therapeutics by 81.4% during the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock valued at $28,000 after buying an additional 33,161 shares during the period. Finally, Squarepoint Ops LLC increased its stake in shares of BioXcel Therapeutics by 203.9% during the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock valued at $27,000 after buying an additional 48,336 shares during the period. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.